Early results from a study of genomewide sequencing support the promise of using plasma cell–free DNA (cfDNA) to develop an early cancer detection test with high specificity, said Geoffrey R. Oxnard, MD, Thoracic Oncologist, Dana-Farber Cancer Institute, Boston, at ASCO 2018.